top of page

YOUNG HOPES IN CARDIOLOGY

logo_ukcl_slo_ang.png

Dear collegues,

We invite you to a short symposium, full of new developments and practical recommendations, which will lead you into the world of making the right decisions at setting the diagnosis and treatment of pulmonary arterial hypertension. Patients with pulmonary hypertension can be encountered everywhere. That is why this symposium is suitable for all specialties. 

 

You can attend the symposium in person or on-line. The lectures will be available on the platform for a whole month, so you can watch only part of the symposium live and the rest at a later date. After the symposium, it will be possible to obtain credit points by completing a questionnaire.

On the behalf of organisers,

Polona Mlakar

Pulmonary arterial hypertension was once a fatal disease. In majority of cases several years passed from the onset of symptoms to the diagnosis. After diagnosis, mortality was greater than 50% within three years. 

 

Prostacyclin was the first effective specific drug. It was rarely used. The route of administration was intravenous, many times difficult and associated with complications. This was followed by the development of drugs that could be administered subcutaneously. Other specific drugs that can be taken orally have also been discovered. 

Following the 3rd WHO Symposium on Pulmonary Hypertension in 2003 in Venice, Italy, a breakthrough in patient management occurred. It has become important to make the diagnosis early and correctly, to make the right decision for the treatment. A modern approach to treatment has evolved. Prognosis and quality of life has improved significantly. Pulmonary arterial hypertension became a chronic disease.

PAH23-2.png
PAH23-4.png
PAH23-1.png

We are delighted to have experts from our neighbouring countries with us for the on-line symposium. We have been working with them for 20 years. During this time, we have established modern management of patients with pulmonary arterial hypertension.

Irene Marthe Lang.png

Prof. dr. Irene Marthe Lang

Galie Nazzareno.png

Prof. dr. Nazzareno Galie

In particular, world-leading experts Prof. Irene Marthe Lang from AKH Vienna, Austria, and Prof. Nazzareno Galie from the University of Bologna, Italy, who has also been the lead expert for all these years for the development of the European guidelines, have played a key role in establishing this. They have helped us both in the management of complex patients and also regarding organisation of patient management. We used the expertise of both of them when we argued with the Health Insurance Fund why we urgently needed expensive specific medicines, for which we are extremely grateful to both of them.

We are also extremely grateful to all our experts and key people at the Health Insurance Fund, who heard our expert’s arguments and made it possible for us to follow all the European recommendations for the modern management of these patients.

Programme and organising committee:

Barbara Salobir, Polona Mlakar, Matevž Harlander  

THE PROGRAM

11:00–11:10 

Welcoming address, 

Medical Director of the University Medical Centre Ljubljana 

MODERN MANAGEMENT OF PAH: ROLE OF PROPER DIAGNOSTICS

(11:10 – 12:50):

 CHAIR:      

Wednesday, January 12, 2022

MONS after MONS 2021| 17:00

NOAK, Antiaggregation, Treatment of arterial hypertension

Thursday, January 13, 2022

MONS before MONS 2022 | 17:00– 19:30

POLYPRAGMASY

Moderator:Miha Šušteršič and Luka Lipar

Friday, January 14, 2022

Exhibition of openings| 13:40-15:30

New AHA-ACC guidelines for chest pain/Matjaž Bunc

Mechanisms of action of SGLT2, Inclisirana, PCSK-9, ARNI, vercigvata /Andraž Cerar

"Mons after Mons" Higlights: SGLT-2, Inclisar

High sensitivity ECG  /Miha Šusteršič

Coronary sinus flow restrictor - CFR /Miha Mrak

Infections and the heart /Janez Tomažič

15:30-15:45  INTRODUCTION | Patient with stable coronary disease: Treatment trends /Matjaž Bunc

Symposium I | 15:45-17:15 

THE LATEST APPROACHES TO LIMITING THE RISKS OF ATHEROSCLEROSIS 

Moderator:Mišo Šabovič and Zlatko Fras

ESC 2021 Highlights: Limiting the risk of AS

Effects of statins, ezetimibe, PCSK9 inhibitors, included / Zlatko Fras

Overview of antidiabetic therapy, new drugs and clinical indications /Aleš Skvarča

Antithrombotic therapy / Gregor Tratar

Renal denervation (RDN), arterial hypertension  / Dragan Kovačić

Optimal clinical practice - patient case /Miran Šebeštjen and Borut Jug

Questions and discussionMišo Šabovič in Zlatko Fras

17:15-17:20  A break

Symposium II | 17:20-18:20 

COMMON DILEMMA IN POLYMORBID PATIENTS 

Moderators:  Boris Krajačič, Simon Terseglav

Polypragmasy / Matej Marinšek

Measures in case of deterioration of kidney function / Jernej Pajek

Interactions between cardiac drugs, pollution and CVD diseases /Miran Brvar

Young people for young people: Polypragmatism Miha Šusteršič

Questions and discussionBoris Krajačič, Simon Terseglav

18:20-18:35 A break

Symposium III| 18:35-19:50

UNSPECIFIED CHEST PAIN 

Moderator:Matjaž Bunc and Miha Čerček

INOCA diagnostics (non-invasive INOCA diagnostics) /Borut Drnovšek

Nucleotide tests /Luka Ležaic

The role of CTA of the coronary arteries and MR of the heart /Tomaž Podlesnikar

Pulmonary hypertension / Polona Mlakar

Covid and the cardiovascular system  / Gradecki outlet

Acute consequences of Covid-19 on the heart: UKC Lj / Andreja Černa Čerček

Questions and discussion /Matjaž Bunc and Miha Čerček

19:50-19:55 A break

Round table | 19:55-20:40

TREATMENT OF THE FUTURE

Moderator:  Igor E. Bergant

 

Genetic diagnostics, genetic treatment /Borut Štrukelj, Borut Peterlin, Robert Zorec 

Closing of the meeting and summary

11:10–11:40 

11:40–11:50

11:50–12:00

12:00–12:10

12:10–12:20

12:20–12:30

12:30–12:50

Where we came from and where we are going in modern diagnostics of PAH /

Prof. Nazzareno Galie, Dept. of Cardiology, Professor of cardiology, Alma Mater Studiorum, University Bologna, Bologna, Italy; Vice-chairman of the Core Network PH of the European Reference Network—LUNG (ERN-LUNG), coordinator of the Guidelines and best Practice of Care committee of ERN-LUNG

Proper diagnostics in specialized centers /

Assist. Polona Mlakar, MD, PhD, Dept. for Pulmonary Diseases and Allergies, University Medical Centre Ljubljana, Slovenia

Role of right heart catheterisation – experiences from our specialized center /

David Lestan, MD, Dept. of Pulmonary Diseases and Allergies, University Medical Centre Ljubljana, Slovenia

Role of noninvasive diagnostic procedures - experiences from our specialized center /

Assist. Prof. Marta Cvijić, MD, PhD, Dept. of Cardiology, University Medical Centre Ljubljana, Slovenia

“PAH associated with connective tissue diseases – most vulnerable group of PAH patients” /

Assist. Prof. Antonija Hočevar, MD, PhD, Dept. of Rheumatology, University Medical Centre Ljubljana, Slovenia

“Role of cardiac echocardiography  in the early detection of PAH in patients with connective tissue diseases – experiences from our specialized center”

Assist. Janez Toplišek, MD, PhD, Dept. of Cardiology, University Medical Centre Ljubljana, Slovenia

Round table with discussion /

All participants

MODERN MANAGEMENT OF PAH: ROLE OF PROPER DECISION MAKING FOR THERAPY

(13:00 – 15:30):

 CHAIR:      

Assist. Prof. Barbara Salobir, MD, PhD, Dept. of Pulmonary Diseases and Allergies, University Medical Centre Ljubljana, Slovenia, Assist. Polona Mlakar, MD, PhD, Dept. for Pulmonary Diseases and Allergies, University Medical Centre Ljubljana, Slovenia

13:00–13:30 

13:30–13:45

13:45–14:00

14:00–14:15

14:15–14:30

14:30–14:45

14:45–15:00

15:00–15:20

15:20–15:30

Where we came from and where we are going in modern therapy of PAH /

Prof. Irene Lang, AKH Vienna, Dept. of Cardiology, AKH Vienna, Professor of Vascular Biology and Cardiology on Medical University of Vienna, Austria. 

»Obstacles in implementation of the 2022 ESC/ERS guidelines on pulmonary hypertension in the routine clinical practice« /

Prof. Arsen Ristić, Division of Cardiology, University Clinical Center of Serbia, Belgrade, Serbia

»Parenteral prostacyclines – still the most effective therapy for PAH« /

Assist. Prof. Nika Skoro Sajer, Dept. of Cardiology, AKH Vienna, Austria

»Better possibilites for long term parenteral prostacyclin therapy with sc. pumps – experiences from AKH Vienna« /

Assist. Prof. Roza Badr-Eslam, Dept. of Cardiology, AKH Vienna, Austria. 

»Proper decision for patient with vasoreactive PAH after clinical deterioration on high doses of calcium channel blockers« /

Prof. Jovan Matijašević, Institute for Pulmonary Diseases of Vojvodina, Dept. of Emergency Pulmonology, Sremska Kamenica, Serbia.

»Long term benefit of combined, oral,  specific therapy for PAH« /

Prim. Ana Hećimović, MD, PhD, , Clinic for lung diseases, University Hospital Centre Zagreb, Croatia

Novelities in therapy of PAH important for clinical practice /

Assist. Prof. Barbara Salobir, MD, PhD, Dept. of Pulmonary Diseases and Allergies, University Medical Centre Ljubljana, Slovenia

Round table with discussion /

All participants

Closing remarks /

Assist. Prof. Matevž Harlander, MD, PhD, Dept. of Pulmonary Diseases and Allergies, University Medical Centre Ljubljana, Slovenia

Organizer:

SiNAPSA - Slovenian Neuroscience Association

The

Technical support:

Plant E-coopedu

The

Contact :

SNC21@sinapsa.org

logo_ukcl_slo_ang.png

Technical and organizational support:

Institute for Professional Education and Innovation Support E-coopedu 

Contact:

info@ecoopedu.com

Web page:

www.ecoopedu.com

E-coopedu_logo.png
bottom of page